Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lysosomal Acid Lipase (LAL) is an enzyme responsible for hydrolyzing cholesterol esters and triglycerides within lysosomes. A deficiency in this enzyme, known as Lysosomal Acid Lipase Deficiency (LAL-D), leads to the intracellular accumulation of these lipids in various tissues and cell types, including the liver, gastrointestinal tract, and vascular endothelium. This accumulation can result in conditions such as Cholesteryl Ester Storage Disease (CESD) and Wolman Disease, characterized by hepatomegaly, liver dysfunction, and hepatic failure. Therapeutic administration of Lysosomal Acid Lipase aims to replace the deficient endogenous enzyme, thereby restoring lipid metabolism and preventing pathological lipid accumulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lysosomal Acid Lipase.